May 4th 2022
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
April 27th 2022
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
April 20th 2022
Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.
Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.
April 6th 2022
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
March 30th 2022
Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.
September 20th 2021
An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.
An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.
September 13th 2021
Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.
Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.
September 7th 2021
Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.
The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.
August 24th 2021
Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Novel strategies being explored in various stages of clinical trials as potential therapies for relapsed/refractory metastatic renal cell carcinoma.
August 17th 2021
Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.
An overview of treatment options for previously treated metastatic renal cell carcinoma.